Related Experiment Videos
Topiramate effectiveness in Prader-Willi syndrome
Sarah A Smathers1, Jacquelyn G Wilson, Michael A Nigro
1Michigan Institute for Neurological Disorders, Farmington Hills, Michigan 48334, USA.
Pediatric Neurology
|April 18, 2003
Summary
Topiramate shows promise in treating Prader-Willi syndrome (PWS). This study found the antiepileptic medication improved mood, reduced self-harm, and stabilized weight in PWS patients.
Area of Science:
- Neurology
- Genetics
- Pharmacology
Background:
- Prader-Willi syndrome (PWS) is a genetic disorder affecting chromosome 15.
- PWS is associated with intellectual disability, obesity, and significant behavioral issues, including self-harm and hyperphagia.
- Existing treatments for PWS behavioral symptoms are limited.
Purpose of the Study:
- To evaluate the efficacy of topiramate in managing behavioral, mood, and eating disorders in Prader-Willi syndrome.
- To explore topiramate's potential to mitigate self-abusive behaviors and compulsive eating in PWS patients.
Main Methods:
- A clinical evaluation of seven patients diagnosed with Prader-Willi syndrome.
- Administration of topiramate to assess its impact on behavior, mood, and weight.
- Monitoring of self-abusive behaviors, mood regulation, and appetite control.
Main Results:
- Topiramate demonstrated a positive effect in reducing self-abusive behaviors.
- Patients experienced improvements in mood regulation.
- The medication contributed to weight stabilization in the evaluated cohort.
Conclusions:
- Topiramate appears to be an effective therapeutic option for specific behavioral manifestations of Prader-Willi syndrome.
- Further research is warranted to confirm these findings and establish optimal dosing and long-term effects.
- Topiramate offers a potential avenue for improving the quality of life for individuals with PWS.